Drug Profile
Dexpramipexole - Areteia Therapeutics
Alternative Names: BIIB-050; KNS-760704; RPPXLatest Information Update: 08 Aug 2023
Price :
$50
*
At a glance
- Originator University of Virginia
- Developer Areteia Therapeutics; Biogen Idec; Knopp Biosciences; National Institute of Allergy and Infectious Diseases
- Class Amines; Antiasthmatics; Benzothiazoles; Neuroprotectants; Small molecules
- Mechanism of Action Antioxidants; Apoptosis inhibitors; Dopamine receptor agonists; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Asthma
- Phase II Amyotrophic lateral sclerosis; Hypereosinophilic syndrome
Most Recent Events
- 03 Aug 2023 Updated efficacy data from the phase II EXHALE-1 trial in Asthma released by Areteia Therapeutics
- 27 Mar 2023 Phase-III clinical trials in Asthma (In adolescents, In adults, In the elderly) in Asia (PO) (Areteia Therapeutics website, October 2022)
- 27 Mar 2023 Phase-III clinical trials in Asthma (In adolescents, In adults, In the elderly) in USA (PO) (NCT05813288)